Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RLS-0071 in Acute Exacerbation of COPD
NCT06175065Phase 2Active, not recruiting
- Sponsor
- ReAlta Life Sciences
- Start
- Jan 2024
- Primary completion
- Jun 2025
- Modality
- Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of pegtarazimod in chronic obstructive pulmonary disease (COPD), sponsored by ReAlta Life Sciences. Started Jan 2024; status: active, not recruiting.
02
Drugs
pegtarazimod
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT06175065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06175065.